Skip to main content
Erschienen in: Drug Safety 9/2017

01.09.2017 | short communication

The Incidence of Drug- and Herbal and Dietary Supplement-Induced Liver Injury: Preliminary Findings from Gastroenterologist-Based Surveillance in the Population of the State of Delaware

verfasst von: Maricruz Vega, Manisha Verma, David Beswick, Stephanie Bey, Jared Hossack, Nathan Merriman, Ashish Shah, Victor Navarro, For the Drug Induced Liver Injury Network (DILIN)

Erschienen in: Drug Safety | Ausgabe 9/2017

Einloggen, um Zugang zu erhalten

Abstract

Background and aim

The population-based incidence rate of drug-induced liver injury (DILI) in the USA is not known. The Drug-Induced Liver Injury Network (DILIN) accrues cases of hepatotoxicity due to medications and herbal and dietary supplements (HDS) from limited geographical areas. The current analysis was an ancillary study of DILIN aimed at determining the annual incidence of DILI in the USA on a population basis, through surveillance in the state of Delaware.

Methods

At the outset of the study, there were 41 gastroenterologists in the state of Delaware and all agreed to participate in surveillance for DILI, which comprised active reporting of suspected cases to the DILIN. The gastroenterologists underwent training in the diagnosis of DILI and were provided with DILIN inclusion criteria. Only cases that met the DILIN laboratory inclusion criteria in 2014 were included in the incidence calculation, and these patients were invited to participate in the DILIN Prospective Study. The number of suspected cases that met inclusion criteria served as the numerator and the 2014 Delaware adult population as the denominator.

Results

During 2014, 23 patients were identified by the surveillance network, 20 of whom met DILIN laboratory inclusion criteria, leading to an incidence of 2.7 cases of DILI per 100,000 adult residents [95% confidence interval (CI) 1.5–3.9 per 100,000]. Fourteen subjects agreed to participate in the DILIN; six declined. Among enrolled cases, the mean age was 51 years, 57% were women, and 71% were white. Eight cases were attributed to antibiotics (36%) and other drugs (21%) and six to HDS (43%). The pattern of injury was hepatocellular in all HDS cases, but only 50% of conventional drug cases (p = 0.05), which more commonly presented with eosinophilia (p = 0.47) and higher alkaline phosphatase levels (p = 0.05). Half of patients were jaundiced, none developed liver failure, and all recovered without the need for transplantation.

Conclusion

Prospective, gastroenterologist-based surveillance for suspected DILI in Delaware yielded an incidence of 2.7 cases per 100,000 adults in 2014; this is the first prospective estimate of DILI for the USA. Because surveillance was limited to subspecialists, the actual incidence of DILI is likely to be higher. These findings provide a benchmark statistic for the epidemiology of DILI in the United States, to be refined with expansion of the surveillance period.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liv Dis. 2002;22(2):145–56.CrossRef Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liv Dis. 2002;22(2):145–56.CrossRef
2.
Zurück zum Zitat Moride Y, Haramburu F, Requejo AA, Bégaud B. Under-reporting of adverse drug reactions in general practice. Br J Clin Pharmacol. 1997;43(2):177–81.CrossRefPubMedPubMedCentral Moride Y, Haramburu F, Requejo AA, Bégaud B. Under-reporting of adverse drug reactions in general practice. Br J Clin Pharmacol. 1997;43(2):177–81.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36(2):451–5.CrossRefPubMed Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36(2):451–5.CrossRefPubMed
4.
Zurück zum Zitat De Valle MB, Av Klinteberg V, Alem N, Olsson R, Björnsson E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther. 2006;24(8):1187–95.CrossRefPubMed De Valle MB, Av Klinteberg V, Alem N, Olsson R, Björnsson E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther. 2006;24(8):1187–95.CrossRefPubMed
5.
Zurück zum Zitat de Abajo FJ, Montero D, Madurga M, García Rodríguez LA. Acute and clinically relevant drug-induced liver injury: a population based case–control study. Br J Clin Pharmacol. 2004;58(1):71–80.CrossRefPubMedPubMedCentral de Abajo FJ, Montero D, Madurga M, García Rodríguez LA. Acute and clinically relevant drug-induced liver injury: a population based case–control study. Br J Clin Pharmacol. 2004;58(1):71–80.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Goldberg DS, Forde KA, Carbonari DM, Lewis JD, Leidi KB, Reddy KR, et al. Population-representative incidence of drug-induced acute liver failure based on an analysis of integrated healthcare system. Gastroenterology. 2015;148(7):1353–61.CrossRefPubMedPubMedCentral Goldberg DS, Forde KA, Carbonari DM, Lewis JD, Leidi KB, Reddy KR, et al. Population-representative incidence of drug-induced acute liver failure based on an analysis of integrated healthcare system. Gastroenterology. 2015;148(7):1353–61.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Galan MV, Potts JA, Silverman AL, Gordon SC. The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center. J Clin Gastroenterol. 2005;39(1):64–7.PubMed Galan MV, Potts JA, Silverman AL, Gordon SC. The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center. J Clin Gastroenterol. 2005;39(1):64–7.PubMed
8.
Zurück zum Zitat Vuppalanchi R, Liangpunsakul S, Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? Am J Gastroenterol. 2007;102(3):558–62.CrossRefPubMed Vuppalanchi R, Liangpunsakul S, Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? Am J Gastroenterol. 2007;102(3):558–62.CrossRefPubMed
9.
Zurück zum Zitat Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419–25.CrossRefPubMed Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419–25.CrossRefPubMed
10.
Zurück zum Zitat Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, DILIN Study Group, et al. Drug-induced liver injury network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32(1):55–68.CrossRefPubMedPubMedCentral Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, DILIN Study Group, et al. Drug-induced liver injury network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32(1):55–68.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Navarro VJ, Barnhart H, Bonkovsky HL, Davern T, Fontana RJ, Grant L, et al. Liver injury from herbals and dietary supplements in the US drug-induced liver injury network. Hepatology. 2014;60(4):1399–408.CrossRefPubMedPubMedCentral Navarro VJ, Barnhart H, Bonkovsky HL, Davern T, Fontana RJ, Grant L, et al. Liver injury from herbals and dietary supplements in the US drug-induced liver injury network. Hepatology. 2014;60(4):1399–408.CrossRefPubMedPubMedCentral
Metadaten
Titel
The Incidence of Drug- and Herbal and Dietary Supplement-Induced Liver Injury: Preliminary Findings from Gastroenterologist-Based Surveillance in the Population of the State of Delaware
verfasst von
Maricruz Vega
Manisha Verma
David Beswick
Stephanie Bey
Jared Hossack
Nathan Merriman
Ashish Shah
Victor Navarro
For the Drug Induced Liver Injury Network (DILIN)
Publikationsdatum
01.09.2017
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 9/2017
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-017-0547-9

Weitere Artikel der Ausgabe 9/2017

Drug Safety 9/2017 Zur Ausgabe